Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Passage Bio's PBGM-01?
PBGM-01 is a gene therapy commercialized by Passage Bio, with a leading Phase II program in GM1 Gangliosidosis (Beta Galactosidase...